NCT05159128

A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-75105186 in Healthy Japanese Participants and a Single Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-75105186 in Healthy Chinese Participants

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Janssen Pharmaceutical K.K. · Industry
• Sex: All
• Age: 20 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of JNJ-75105186 after single ascending oral dose administration in healthy Japanese participants and after single oral dose administration in healthy Chinese participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-75105186	JNJ-75105186 will be administered orally in Part 1 and 2.
OTHER	Placebo	Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.

Timeline

• Start date: 2021-11-15
• Primary completion: 2022-04-02
• Completion: 2022-04-02
• First posted: 2021-12-15
• Last updated: 2025-02-03

Locations

1 site across 1 country: Japan